This poster presents Ncardia’s human iPSC-derived neuronal assays designed to model key protein aggregation mechanisms underlying Parkinson’s disease, Alzheimer’s disease, and ALS.
Download it now for a closer look at:
How α-synuclein pre-formed fibrils induce phosphorylation and aggregation in human neuronal cultures, creating quantifiable Parkinson’s disease–relevant readouts.
Tau overexpression combined with chronic Tau PFF exposure, generating misfolded, phosphorylated, and insoluble Tau species characteristic of Alzheimer’s pathology.
Human iPSC-derived motor neurons modeling TDP-43 mislocalization, aggregation, STMN2 reduction, and truncated STMN2 formation linked to ALS.
Electrophysiological readouts showing how protein aggregation disrupts neuronal network activity.
Automated, scalable assay formats with strong performance metrics (Z-factor > 0.5), suitable for screening aggregation-targeting therapeutics.
Whether you are studying early aggregation biology or advancing compounds into structured screening workflows, these human iPSC-derived proteinopathy models provide a reproducible platform to evaluate therapeutic strategies targeting α-synuclein, Tau, and TDP-43 driven neurodegeneration.